Sep 15, 2020 / 01:30PM GMT
David Ryan Lewis - Morgan Stanley, Research Division - MD
Well, good morning, everyone, and welcome to day 2 of the Morgan Stanley Healthcare Conference 2020. My name is David Lewis, medical device analyst at Morgan Stanley.
It's my pleasure to start off this morning with Haemonetics. As many of you know, Haemonetics, under the leadership of Chris Simon in these last few years, has really gone through a significant transformation from both a growth technology and cost perspective. We're going to talk about some of that this morning. And then there's been some recent debates on Haemonetics we're also going to focus on as well.
Before we begin, as I've said time and time again, please go to the Morgan Stanley website under Research Disclosures, morganstaley.com/researchdisclosures to see all of my disclosures.
And with that, we're going to get right into it with Chris this morning.
Questions and Answers:
David Ryan Lewis - Morgan Stanley, Research Division - MDSo Chris, I want to start sort of with the key debate of the hour.